Research on prognostic factors in gliomas has identified critical biomarkers that can influence patient outcomes significantly. One notable study examined the expression levels of transcription factors EGR1 and EGR3 in gliomas, revealing that high EGR1 expression correlated with a methylated MGMT promoter in 83% of patients. This finding suggests a potential link between EGR1 expression and the molecular characteristics of gliomas, which may influence treatment responses. Furthermore, the study found that high EGR3 expression in patients with MGMT-methylated tumors was associated with poorer survival outcomes, with a hazard ratio (HR) of 1.98 (95% CI 1.22-3.22; P = 0.006). This indicates that EGR3 may serve as a negative prognostic marker in this subgroup of patients (ref: Knudsen doi.org/10.1038/s41598-020-66236-x/). The interplay between EGR1 and EGR3 expression levels further elucidates their prognostic significance. Specifically, patients exhibiting high levels of both EGR1 and EGR3 had a significantly worse survival prognosis compared to those with high EGR1 and low EGR3 levels, with an HR of 2.11 (95% CI 1.25-3.56; P = 0.005). These findings underscore the complexity of glioma biology and highlight the necessity for further investigation into how these transcription factors can be integrated into clinical practice to better stratify patients based on their risk profiles. Overall, the study emphasizes the potential of EGR1 and EGR3 as valuable prognostic indicators that could guide therapeutic decisions in glioma management.